Targeting Cancer Immunotherapy: Development of an HTS Method Using the Transcreener® ENPP1 Assay
Discover ENPP1 Inhibitors with the Transcreener AMP2/GMP2 Assay
The Transcreener AMP²/GMP² ENPP1 Assay directly measures the GMP and (or) AMP produced by ectonucleotide pyrophosphatase/phosphodiesterase 1 (also known as ENPP1). By measuring the production of AMP and GMP researchers can effectively determine the activity of the ENPP1 enzyme. The assay provides a powerful tool to screen entire compound libraries for ENPP1 modulators to help find new therapeutics for diseases such as cancer.
ENPP1 is Critical for Purinergic Signalling
ENPP1 is a nucleotide pyrophosphatase and phosphodiesterase that regulates purinergic signaling and can degrade different nucleotides including ATP and cGAMP. ENPP1 has been identified as the primary enzyme responsible for degrading cGAMP and therefore is under intense investigation as a therapeutic target for cancer immunotherapy.
Direct Detection of AMP and GMP to Measure ENPP1 Enzymatic Activity


Recent Posts
Exploring the Use of NUDT5 Inhibitors to Treat Breast Cancer
The Role of CD38 Activity in the Impaired Immune Response
New Publication by the Scientists at BellBrook Labs – Development of a High-Throughput Assay to Identify Inhibitors of ENPP1
Using a Universal GMP Assay for PDE Research
ST6GAL1 Drug Discovery to Combat Cancer